¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"enzyme trace substance theory"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • substance P
    ¼­ºê½ºÅĽºP, ¹°ÁúP
  • substance withdrawal
    ¹°Áú±Ý´Ü
  • slow-reacting substance
    Áö¿¬¹ÝÀÀ¹°Áú
  • visual substance
    ½Ã°¢¹°Áú
  • volatile substance
    Èֹ߹°Áú
  • white substance
    ¹é(»ö)Áú
  • zymoplastic substance
    ÀÀÇ÷ÃËÁø¹°Áú
  • angiotensin converting enzyme
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • brancher enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • spontaneous generation theory
    ÀÚ¿¬¹ß»ý¼³
  • supersaturation/crystallization theory
    °úÆ÷È­°áÁ¤È­¼³
  • theory
    Çм³, ¼³, ÀÌ·Ð
  • template theory
    Ç×ü»ý»êÁö½Ã¼³, Ç×ü»ý»êÃø¼â¼³
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤¹ý
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò(ß«ûùü»êªý£áÈ).
  • reducing enzyme
    ȯ¿øÈ¿¼Ò(ü½êªý£áÈ).
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò(¡­ý£áÈ).
  • C-substance
    C-¹°Áú.
  • EPS=£¾exophthalmos producing substance
    ¾È±¸µ¹ÃâÀ¯¹ß¹°Áú.
  • Goitrogenic substance
    °©»ó¼±Á¾À¯¹ß¹°Áú(Ë£ßÒàÍðþë¯Û¡Úªòõ)
  • Inducer substance
    À¯µµ¹°Áú(ë¯ÓôÚªòõ)
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • Kerry reducing substance test
    Äɸ®È¯¿ø¹°Áú½ÃÇè
  • Mullerian inhibiting substance
    ¹°·¯°ü ¾ïÁ¦¹°Áú
  • P substance
    P¹°Áú
  • SRS A : slow reacting substance A
    ¿¡½º¾Ë¿¡½º-¿¡ÀÌ.
  • accelerans substance
    ÃËÁø¹°Áú(õµòäÚªòõ).
  • accessory food substance
    ºÎ¿µ¾ç¹°(Üùç½å×Úª).
  • acrosomal substance
    ÷´Üü¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • enzyme antibody technique
    È¿¼ÒÇ×ü¹ý.
  • enzyme assay
    È¿¼ÒÃøÁ¤(¹ý)
  • enzyme deficiency
    È¿¼Ò°áÇÌ(Áõ)
  • enzyme glaucoma
    È¿¼Ò³ì³»Àå
  • enzyme immunoassay
    È¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • enzyme immunoassay (EIA)
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme immunoassay(EIA)
    È¿¼Ò ¸é¿ªÃøÁ¤¹ý
  • enzyme induction
    È¿¼ÒÀ¯µµ(ý£áÈë¯Óô).
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦.
  • enzyme inhibitor
    È¿¼ÒÀúÇØÁ¦.
  • enzyme label(l)ing
    È¿¼ÒÇ¥Áö.
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü.
  • enzyme labelling
    È¿¼ÒÇ¥Áö
  • enzyme linked immunosorbent assay (ELISA)
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme measurement
    È¿¼ÒÃøÁ¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • membron theory
    ¸Éºê·ÐÀÌ·Ð(ìµÖå)
  • molecular orbital theory
    ºÐÀڱ˵µ¼³(ÝÂí­ÏùÔ³àã)
  • Morawitz theory
    ¸ð¶óºñÃ÷¼³(àã)
  • mosaic theory
    ¸ðÀÚÀÌÅ©¼³(àã)
  • multistep induction theory
    ´Ù´Ü°è À¯µµ·Ð(ÒýÓ«Í­ë¯ÓôÖå)
  • mutation theory
    º¯ÀÌ·Ð(ܨì¶Öå)
  • neutral theory of molecular evolution
    Á߸³ºÐÀÚÁøÈ­·Ð(ñ騡ÝÂí­òäûùÖå)
  • oncogene theory
    ¾ÏÀ¯ÀüÀÚÀÌ·Ð(äßë¶îîí­ìµÖå)
  • one-hit theory
    Àϰݼ³(àã)
  • plate theory
    ÆòÆÇÀÌ·Ð(øÁ÷ù×âÖå)
  • polyaffinity theory
    ´Ùģȭ¼º ÀÌ·Ð(ÒýöÑûúàõ×âÖå)
  • polyetiological theory
    ´ÙÀÎ ÀÌ·Ð(Òýì××âÖå)
  • prothrombin derivatives theory
    ÇÁ·ÎÆ®·Òºó À¯µµÃ¼ ÀÌ·Ð(ë¯Óôô÷×âÖå)
  • quantum theory
    ¾çÀÚ·Ð(åÕí­Öå)
  • recapitulation theory
    ¹Ýº¹ ¹ß»ý·Ð(ÚãÜÖÛ¡ßæÖå)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SPS Sleep Promoting Substance
SRS-A Slow Reacting Substance of Anaphylaxis
ADS acute death syndrome; acute diarrheal syndrome; Alcohol Dependence Scale; alternative delivery syste...
ALS acute lateral sclerosis; advanced life support; afferent loop syndrome; amyotrophic lateral sclerosi...
AMS ablepharon-microstomia syndrome; acute mountain sickness; adenosylmethionine synthetase; aggravated ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HSS Hepatic Stimulatory Substance
I-SP Immunoreactive substance P
ir SP Immunoreactive substance P
MIS Muellerian inhibiting substance
PSUD Psychoactive Substance Use Disorder
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • corrosive substance
    ºÎ½Ä ¹°Áú, ºÎ½Ä¼º ¹°Áú
  • cytotoxic substance
    ¼¼Æ÷ µ¶, ¼¼Æ÷µ¶¼Ò
    µ¿ÀǾî=cytotoxin.
  • endobiotic substance
    ³»»ýÀû ¹°Áú
  • ferromagnetic substance
    öÀÚ¼º ü, °­ÀÚ¼º ü
  • intercelluar substance
    ¼¼Æ÷°£ ¹°Áú
  • intercellular substance
    ¼¼Æ÷ °£Áú, ¼¼Æ÷°£ ¹°Áú
    ¼¼Æ÷¿Í ¼¼Æ÷ »çÀ̸¦ ä¿ì´Â ¹°Áú. ±âÁúÀ̶ó°íµµ ÇÑ´Ù. ÁÖµÈ ¼ººÐÀº È÷¾Ë¿ì·Ð»êÀ̳ª Äܵå·ÎÀÌÆ¾ Ȳ»ê µîÀÇ Á¡¾× ´Ù´çÀ» ÁÖ·ÎÇÏ´Â ´Ü¹éÁú ´Ù´çÀÌ´Ù. »À Á¶Á÷¿¡¼­´Â Ä®½· ¿°, ¸¶±×³×½· ¿°À» ¼¼Æ÷°£ ¹°Áú·Î¼­ ÇÔÀ¯Çϰí ÀÖ´Ù.
  • lateral intermediate substance
    °¡ÂÊ Áß°£ ȸ»öÁú
  • lens substance
    ¼öÁ¤Ã¼ ¹°Áú, ¼öÁ¤Ã¼ Áú
  • medullary substance
    ¼öÁú
    Ãà»è°ú ¼öÃʸ¦ ÀÌ·ç´Â ÁßÃ߽Űæ°èÀÇ ¹éÁú. ±â°ü ³»ºÎÀÇ À¯¿¬ÇÑ °ñ¼ö¾ç ¹°Áú.
  • nutrient substance
    ¿µ¾ç ¹°Áú
  • odoriferous substance
    Çâ·á
  • osteoid substance
    Dz »À ¹°Áú
  • pain producing substance
    µ¿Åë À¯¹ß ¹°Áú
  • psychoactive substance-induced organic mental disorder
    ȰÁ¤½Å¼º ¹°Áú·Î À¯µµµÈ ±âÁúÀû Á¤½Å Àå¾Ö
    ȰÁ¤½Å¼º ¹°ÁúÀÇ »ç¿ë°ú °ü·ÃµÈ ±âÁúÀû ³ú ÁõÈÄ. ¿­ °¡Áö Ư¼ö ÁõÈĸ¦ Æ÷ÇÔÇϰí Àִµ¥ Áßµ¶, Áß´Ü Áõ»ó, ¼¶¸Á, Ä¡¸Å, °Ç¸Á Àå¾Ö, ¸Á»ó Àå¾Ö, ȯ°¢, °¨Á¤ Àå¾Ö, Áö°¢ Àå¾Ö ¹× ÀÎ°Ý Àå¾Ö µîÀÌ´Ù. ¾ËÄÝ Áßµ¶°ú °°ÀÌ ¿øÀÎ ¹°ÁúÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸é À̸¦ ¸í±âÇÑ´Ù.
  • radioactive substance
    ¹æ»ç¼º ¹°Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
specific capsular substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
spongy substance Bone in which the spicules or trabeculae form a three-dimensional latticework (cancellus) with the interstices filled with embryonal connective tissue or bone marrow.
Synonym: substantia trabecularis, cancellous bone, spongy bone, spongy substance, trabecular bone.
(05 Mar 2000)
standard substance A pure, authentic substance used for identification purposes.
(05 Mar 2000)
Stilling's gelatinous substance The central gray matter of the spinal cord surrounding the central canal.
Synonym: substantia intermedia centralis et lateralis, anterior gray column, Stilling's gelatinous substance, substantia gelatinosa centralis.
(05 Mar 2000)
neurosecretory substance The secretion of nerve cell bodies located in the hypothalamus; the substance is transported by way of hypothalamo-hypophysial tract fibres into the neurohypophysis where the terminals of the nerve fibres contain the secretion. As seen in the fibres and terminals with a light microscope, the substance appears as Herring bodies or hyaline bodies of the pituitary (see under body).
See: hyaline bodies of pituitary.
(05 Mar 2000)
Nissl substance The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites.
Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance.
(05 Mar 2000)
substance The material constituting an organ or body, also called substantia.
Origin: L. Substantia
(18 Nov 1997)
substance abuse Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems.
(05 Mar 2000)
substance abuse detection Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection.
(12 Dec 1998)
substance abuse disorders A class of mental disorders in which behavioural and biological changes are associated with regular use of alcohol, drugs, and related substances that affect the central nervous system and personal and social functioning.
(05 Mar 2000)
substance abuse, intravenous Abuse, overuse, or misuse of a substance by its injection into a vein.
(12 Dec 1998)
substance abuse treatment centres Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centres are included.
(12 Dec 1998)
substance dependence A pattern of behavioural, physiologic, and cognitive symptoms that develop due to substance use or abuse; usually indicated by tolerance to the effects of the substance and withdrawal symptoms that develop when use of the substance is terminated.
(05 Mar 2000)
substance-induced organic mental disorders Mental disorders caused by use of drugs, e.g., cocaine.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á